<DOC>
	<DOCNO>NCT01547689</DOCNO>
	<brief_summary>The primary purpose study evaluate safety tolerability UC-MSC ( Human Umbilical Cord-Derived Mesenchymal Stem Cell ) .This study also investigate efficacy treatment patient Alzheimer 's disease ( AD ) .</brief_summary>
	<brief_title>Safety Efficiency Umbilical Cord-derived Mesenchymal Stem Cells ( UC-MSC ) Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>To date , AD patient seek treatment already neuritic plaque , neurofibrillary tangle , neurodegeneration . At stage disease , perhaps multi-faceted approach halt toxicity amyloid-β peptide promote cell survival and/or replace lose cell would beneficial.Most treatment Alzheimer disease chemical drug improve symptom able inhibit disease progression . Mesenchymal stem cell ( MSCs ) multipotent cell clinically explore new therapeutic treating variety immune-mediated diseases.Preclinical study mechanism action suggest therapeutic effect afford MSC transplantation short-lived related dynamic , paracrine interaction MSCs host cells.Clinical trial MSCs thus far show adverse reaction allogeneic versus autologous MSC transplant . Clinical study show umbilical cord derive MSC immunologically stable toxic . This study evaluate safety tolerability UC-MSC ( Human Umbilical Cord-Derived Mesenchymal Stem Cell ) .This study also investigate efficacy treatment patient Alzheimer 's disease .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Men woman age range 50 85 All woman : go menopause Probable Alzheimer 's disease determine NINCDSADRDA criterion MMSE score 3 20 , inclusive Voluntarily participate subject sign consent form Subject cancer Subject positive test Human Immunodeficiency Virus ( HIV ) Subject undergo Magnetic Resonance Imaging ( MRI ) , compute tomography ( CT ) screen Subject psychological disease ( i.e . depression , schizophrenia , bipolar disorder , etc ) Subject dementia cause Alzheimer 's disease ( i.e . infection central nervous system , CreutzfeldJacob disease , severe head trauma , Pick 's disease , Huntington 's disease , Parkinson 's disease ) Subject vascular dementia determine clinical criterion Design Standards Manual ( DSM ) IV image criterion Erkinjuntii Subject severe white matter hyperintensities ( WMH ) ; Severe WMH define length deep white matter 25 mm long length periventricular capping/banding 10 mm longer . Subject stroke 3 month . Subject severe kidney failure ( 1.5 mg/dL serum creatinine ) Hemoglobin &lt; 9.5 g/dL men , &lt; 9.0 g/dL woman ; Total WBC count &lt; 3000/mm3 ; Total bilirubin ≥ 3 mg/dL Subject suspect active lung disease base check Xray result Subject exclude subject selection process study A platelet count &lt; 150,000/mm3 ; Plasma prothrombin time ( PT ) ≥ 1.5 ; international normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) ≥ 1.5X control value Subject determine inappropriate investigator</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>